[go: up one dir, main page]

AU2022393234A1 - Injectable and inhalable formulations - Google Patents

Injectable and inhalable formulations Download PDF

Info

Publication number
AU2022393234A1
AU2022393234A1 AU2022393234A AU2022393234A AU2022393234A1 AU 2022393234 A1 AU2022393234 A1 AU 2022393234A1 AU 2022393234 A AU2022393234 A AU 2022393234A AU 2022393234 A AU2022393234 A AU 2022393234A AU 2022393234 A1 AU2022393234 A1 AU 2022393234A1
Authority
AU
Australia
Prior art keywords
formulation
dimethyltryptamine
compound
salt
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022393234A
Other languages
English (en)
Inventor
Tiffanie BENWAY
Meghan Good
Ellen James
Zelah JOEL
Marie LAYZELL
Peter RANDS
Carol Routledge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cybin UK Ltd
Original Assignee
Cybin UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TW110143066A external-priority patent/TWI891942B/zh
Priority claimed from GBGB2119021.0A external-priority patent/GB202119021D0/en
Application filed by Cybin UK Ltd filed Critical Cybin UK Ltd
Publication of AU2022393234A1 publication Critical patent/AU2022393234A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2022393234A 2021-11-18 2022-11-18 Injectable and inhalable formulations Pending AU2022393234A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
AUPCT/EP2021/082227 2021-11-18
TW110143066 2021-11-18
TW110143066A TWI891942B (zh) 2020-12-01 2021-11-18 氘化化合物
PCT/EP2021/082227 WO2022117359A1 (fr) 2020-12-01 2021-11-18 Composés de n,n-diméthyltryptamine deutérés ou partiellement deutérés
GBGB2119021.0A GB202119021D0 (en) 2021-11-18 2021-12-24 Injectable and inhalable formulations
GB2119021.0 2021-12-24
US202217574424A 2022-01-12 2022-01-12
US17/574,424 2022-01-12
EPPCT/EP2022/055324 2022-03-02
EP2022055324 2022-03-02
PCT/EP2022/082486 WO2023089132A1 (fr) 2021-11-18 2022-11-18 Formulations injectables et inhalables

Publications (1)

Publication Number Publication Date
AU2022393234A1 true AU2022393234A1 (en) 2024-06-06

Family

ID=84440034

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022393234A Pending AU2022393234A1 (en) 2021-11-18 2022-11-18 Injectable and inhalable formulations

Country Status (11)

Country Link
EP (1) EP4433049A1 (fr)
JP (1) JP2024540527A (fr)
KR (1) KR20240110836A (fr)
AU (1) AU2022393234A1 (fr)
CA (1) CA3238583A1 (fr)
CL (1) CL2024001452A1 (fr)
CO (1) CO2024007518A2 (fr)
IL (1) IL312859A (fr)
MX (1) MX2024005955A (fr)
WO (1) WO2023089132A1 (fr)
ZA (1) ZA202403906B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021276656A1 (en) 2020-05-19 2022-11-24 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101687788A (zh) * 2006-10-19 2010-03-31 奥斯拜客斯制药有限公司 取代的吲哚
AU2020225410B2 (en) * 2019-02-22 2025-10-30 GH Research Ireland Limited 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for treating depression
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
AU2020381103B2 (en) 2019-11-07 2022-08-11 Cybin Uk Ltd Compounds
EP3902541B1 (fr) 2020-06-02 2022-09-14 Small Pharma Ltd Compositions thérapeutiques comprenant des composés de n,n-dimethyltryptamine deutérés ou partiellement deutérés
CA3179335C (fr) * 2020-08-28 2024-03-05 Small Pharma Ltd Formulation injectable
EP4031529B1 (fr) * 2020-12-01 2023-09-27 Small Pharma Ltd Composés de n,n-diméthyltryptamine deutérés ou partiellement deutérés

Also Published As

Publication number Publication date
EP4433049A1 (fr) 2024-09-25
MX2024005955A (es) 2024-06-11
CO2024007518A2 (es) 2024-07-29
JP2024540527A (ja) 2024-10-31
IL312859A (en) 2024-07-01
KR20240110836A (ko) 2024-07-16
CA3238583A1 (fr) 2023-05-25
ZA202403906B (en) 2025-08-27
CL2024001452A1 (es) 2024-09-27
WO2023089132A1 (fr) 2023-05-25

Similar Documents

Publication Publication Date Title
US12318477B2 (en) Injectable and inhalable formulations
US11406619B2 (en) Injectable formulations
KR102636385B1 (ko) 주사용 제제
US20220062237A1 (en) Injectable formulation
US12251371B2 (en) Deuterated or partially deuterated N,N-dimethyltryptamine compounds
EP4031529A1 (fr) Composés de n,n-diméthyltryptamine deutérés ou partiellement deutérés
Layzell et al. Injectable formulation
WO2022117640A1 (fr) Formulations inhalables
AU2022393234A1 (en) Injectable and inhalable formulations
US20250032450A1 (en) Injectable and inhalable formulations
US20250262145A1 (en) Injectable and inhalable formulations
US20220169606A1 (en) Compositions and compounds for bioanalysis
CN118450893A (zh) 可注射和可吸入的制剂
EA049106B1 (ru) Инъекционная композиция
HK40115195A (en) Injectable formulation
BR112022022198B1 (pt) Formulação injetável
HK40089095A (en) Injectable formulation
HK40089095B (en) Injectable formulation